Medicare AdvantagePrior AuthMedium impact
Tobramycin for Inhalation (Revised)
Humana·Pulmonology, Pediatrics, Internal Medicine +1 more·Medicare Advantage
Effective date
Jan 1, 2024
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage now requires prior authorization for all tobramycin inhalation products (Tobi, Kitabis, Bethkis, Tobi Podhaler) used to treat cystic fibrosis or bronchiectasis with Pseudomonas aeruginosa colonization. Brand name products require additional documentation showing prior therapy with or intolerance to generic tobramycin.
Action Required
Immediately: Update prior authorization protocols for all tobramycin inhalation products for Humana Medicare Advantage patients. Ensure documentation includes: 1) Confirmed diagnosis of cystic fibrosis or bronchiectasis, 2) Evidence of Pseudomonas aeruginosa colonization, 3) For brand requests, documentation of prior therapy with or intolerance to generic tobramycin. Train clinical staff to obtain prior auth before prescribing. Claims will be denied without proper authorization.